# BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

> **NCT06704152** · PHASE1,PHASE2 · RECRUITING · sponsor: **BlueSphere Bio, Inc** · enrollment: 38 (estimated)

## Conditions studied

- AML, Adult Recurrent
- ALL, Recurrent, Adult
- MDS

## Interventions

- **DRUG:** SOC + BSB-1001 Dose Escalation Cohort
- **DRUG:** SOC+BSB-1001 Expansion Dose

## Key facts

- **NCT ID:** NCT06704152
- **Lead sponsor:** BlueSphere Bio, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-04
- **Primary completion:** 2029-02
- **Final completion:** 2029-03
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06704152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06704152, "BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06704152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*